Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dose reduction of darunavir/ritonavir once daily in virologically suppressed HIV-1 patients
2011-006272-39Phase 4Completed
- Sponsor
- Fight AIDS and Infectious Diseases Foundation
- Start
- Feb 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, single-arm trial of darunavir in Human immunodeficiency virus infection type 1, sponsored by Fight AIDS and Infectious Diseases Foundation. Primary endpoint: Virologic suppression at 48 weeks. Started Feb 2012; status: completed.
02
Drugs
darunavir
03
Conditions
Human immunodeficiency virus infection type 1
Beyond the preview
Go deeper on 2011-006272-39.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-006272-39.